Article info

Original research
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease

Authors

  1. Correspondence to Dr Elena Tomaselli Muensterman; elena.muensterman{at}takeda.com
View Full Text

Citation

McDonnell SRP, Nguyen VA, Walton NM, et al
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease

Publication history

  • Received November 22, 2023
  • Accepted February 15, 2024
  • First published March 7, 2024.
Online issue publication 
March 07, 2024
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.